Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This emerging Bitcoin infrastructure company is building a vertically integrated model (click to learn more) Laser Photonics Announces Strategic Milestone on Advanced Laser Shield Anti Drone System (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Tempus AI Inc TEM

Technology Health Information Services
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the... see more

Recent & Breaking News (NDAQ:TEM)

Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring

Business Wire 7 hours ago

Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026

Business Wire 1 day ago

Tempus Launches Automated "Active Follow-Up" Service to Support Guideline-Concordant Care

Business Wire 2 days ago

Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE

Business Wire 6 days ago

Tempus to Present at the 25th Annual Needham Virtual Healthcare Conference

Business Wire 6 days ago

Tempus and Medtronic Announce ALERT Trial Results Showing AI-Driven EHR Notifications Improve Treatment for Significant Valvular Heart Disease

Business Wire April 1, 2026

Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries

Business Wire March 17, 2026

Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings

Business Wire March 11, 2026

Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine

Business Wire March 3, 2026

Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference

Business Wire February 26, 2026

Tempus Reports Fourth Quarter and Full Year 2025 Results

Business Wire February 24, 2026

Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm

Business Wire February 18, 2026

Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform

Business Wire February 12, 2026

Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24

Business Wire February 10, 2026

Ambry's Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes

Business Wire February 4, 2026

Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield

Business Wire February 2, 2026

Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers

Business Wire January 27, 2026

Tempus Announces the Launch of Paige Predict

Business Wire January 21, 2026

Tempus and NYU Langone Health Announce Strategic Collaboration to Advance Precision Oncology

Business Wire January 12, 2026

Northwestern Medicine Selects Tempus to Expand Genomic Testing

Business Wire January 12, 2026

Podcasts